Adverse events3,395

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

21 to 40 of 3,395

Download this page as JSON

Type	Event	Organ system	Group	Affected	At risk
other	Pyrexia	General disorders	Phase 2, Cohort 4: Entinostat 5 mg Weekly + Pembrolizumab	1	38
other	Pain	General disorders	Phase 1b (Dose Escalation): Entinostat 3 mg Weekly + Pembrolizumab	1	6
other	Pain	General disorders	Phase 1b (Dose Escalation): Entinostat 5 mg Weekly + Pembrolizumab	2	7
other	Pain	General disorders	Phase 1b (Dose Confirmation): Entinostat 5 mg Weekly + Pembrolizumab	2	9
other	Pain	General disorders	Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab	3	18
other	Pain	General disorders	Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab	10	76
other	Pain	General disorders	Phase 2, Cohort 3: Entinostat 5 mg Weekly + Pembrolizumab	4	53
other	Pain	General disorders	Phase 2, Cohort 4: Entinostat 5 mg Weekly + Pembrolizumab	1	38
other	Chills	General disorders	Phase 1b (Dose Escalation): Entinostat 3 mg Weekly + Pembrolizumab	0	6
other	Chills	General disorders	Phase 1b (Dose Escalation): Entinostat 5 mg Weekly + Pembrolizumab	0	7
other	Chills	General disorders	Phase 1b (Dose Confirmation): Entinostat 5 mg Weekly + Pembrolizumab	1	9
other	Chills	General disorders	Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab	1	18
other	Chills	General disorders	Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab	3	76
other	Chills	General disorders	Phase 2, Cohort 3: Entinostat 5 mg Weekly + Pembrolizumab	7	53
other	Chills	General disorders	Phase 2, Cohort 4: Entinostat 5 mg Weekly + Pembrolizumab	4	38
other	Non-cardiac chest pain	General disorders	Phase 1b (Dose Escalation): Entinostat 3 mg Weekly + Pembrolizumab	1	6
other	Non-cardiac chest pain	General disorders	Phase 1b (Dose Escalation): Entinostat 5 mg Weekly + Pembrolizumab	0	7
other	Non-cardiac chest pain	General disorders	Phase 1b (Dose Confirmation): Entinostat 5 mg Weekly + Pembrolizumab	0	9
other	Non-cardiac chest pain	General disorders	Phase 2, Cohort 1: Entinostat 5 mg Weekly + Pembrolizumab	1	18
other	Non-cardiac chest pain	General disorders	Phase 2, Cohort 2: Entinostat 5 mg Weekly + Pembrolizumab	4	76

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous page Next page

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02437136/events?page=2

API reference For AI assistants